Trials / Completed
CompletedNCT00956553
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Public Health England · Other Government
- Sex
- Female
- Age
- 13 Years – 15 Years
- Healthy volunteers
- Accepted
Summary
This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.
Detailed description
This study looks at possible cross reactivity between different HPV serotypes and both peripheral antibodies and mucosally-secreted antibodies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cervarix | Three doses of Cervarix at month 0, 1 and 6. |
| BIOLOGICAL | Gardasil | Three doses of Gardasil at month 0, 1 and 6. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2012-09-01
- Completion
- 2013-09-01
- First posted
- 2009-08-11
- Last updated
- 2020-10-01
Locations
3 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00956553. Inclusion in this directory is not an endorsement.